Insulet (NASDAQ:PODD) Downgraded by Wall Street Zen to Hold

Insulet (NASDAQ:PODD) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

PODD has been the subject of a number of other reports. Truist Financial reaffirmed a “hold” rating and issued a $153.00 target price (down from $210.00) on shares of Insulet in a report on Wednesday, August 5th. Evercore set a $180.00 price objective on shares of Insulet in a research note on Monday, July 6th. Royal Bank Of Canada dropped their target price on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. restated a “neutral” rating and set a $152.00 price objective (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Finally, Jefferies Financial Group reduced their target price on shares of Insulet from $275.00 to $190.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $186.68.

Insulet Stock Performance

NASDAQ PODD opened at $149.01 on Friday. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The firm has a market capitalization of $10.33 billion, a P/E ratio of 27.85, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. The stock’s fifty day moving average is $140.58 and its two-hundred day moving average is $154.66.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same period last year, the company earned $1.17 EPS. The company’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts anticipate that Insulet will post 6.51 earnings per share for the current year.

Institutional Trading of Insulet

Several hedge funds have recently made changes to their positions in PODD. OneDigital Investment Advisors LLC bought a new stake in Insulet in the 2nd quarter worth about $6,741,000. OP Asset Management Ltd purchased a new stake in Insulet during the first quarter valued at approximately $1,513,000. Amundi lifted its stake in Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after acquiring an additional 60,929 shares during the period. Headlands Technologies LLC boosted its stake in shares of Insulet by 2,041.5% during the 2nd quarter. Headlands Technologies LLC now owns 31,930 shares of the medical instruments supplier’s stock worth $4,861,000 after acquiring an additional 30,439 shares in the last quarter. Finally, SEB Asset Management AB purchased a new position in Insulet in the 1st quarter valued at $24,700,000.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.